Clinical Trial Update: Efficacy and Safety Study of Benralizumab Added to Medium-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating benralizumab as add-on therapy to medium-dose inhaled corticosteroid plus LABA in uncontrolled asthma was terminated; results were po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Benralizumab (benralizumab)

Snippet

Sponsor: AstraZeneca | Conditions: Asthma | Phase 3 | Status: TERMINATED | Results posted: 2015-11-23